Data are summarised using standard descriptive statistics. Analysis was by intention-to-treat. Analysis of associations between categorical variables used Pearson's χ 2 and McNemar tests for independent and paired samples, respectively. For continuous variables, Mann-Whitney's U-test was performed for non-parametric data. Binary logistic regression was used to assess variables associated with baseline MetS and multiple logistic regression was used to adjust for potential confounders. Efficacy evaluation involved comparing anthropometric, blood pressure and laboratory measures at baseline and intervention completion. Mean differences were calculated and compared using paired sample t-tests. All P-values of o 0.05 (two-tailed) were considered significant. Statistical analyses were performed with SPSS software (version 21.0, IBM Corp, Armonk, NY, USA).
Fifty-three participants (53% female) were recruited with a median age at enrolment of 47.8 (range, 24.7-67.6) years. The median time since either autologous (32%) or allogeneic (68%) transplantation was 5.1 (range, 2-15.4) years. Table 1 outlines the participant demographic and clinical characteristics. There was no statistically significant difference between autologous or allogeneic SCT recipients in any measured parameter, therefore, the group was considered as a whole for all analyses. Four patients did not complete the program citing personal reasons.
MetS prevalence at baseline was 43% (95% confidence interval (CI):30.2-56.6) with 36% of participants having at least two ATP-III criteria for MetS. The most prevalent of the MetS components was central obesity (85%; 95% CI:75.5-94.3), followed by hypertriglyceridemia (43%; 95% CI:28.3-54.7), reduced HDL-cholesterol (36%; 95% CI:22.6-49.1) and hyperglycaemia (30%; 95% CI:18.9-41.5). Overweight/obesity classified by BMI was present in 68% (95% CI:54.7-79.2). Compared with those of normal BMI, MetS was more prevalent in the overweight/obese group (53% vs 24%, P = 0.05; odds ratio (OR) 3.63; 95% CI:1.0-13.3). The presence of MetS was significantly associated with male gender (OR 3.75; 95% CI:1.2-11.8) and remained so after controlling for age, transplant type and BMI, P = 0.02.
From baseline to intervention end, participants lost an average 2.2 kg of weight, 0.8 BMI units and 2.8 cm in waist circumference (all Po 0.001, Table 2 ). Of those with MetS at baseline, 22% (5/23) no longer met MetS criteria at intervention completion. Reduction of ⩾ 1 MetS component occurred in 21% of participants. Significant improvements in HDL-cholesterol (mean difference 0.1 mmol/L, P = 0.004) and reductions in systolic and diastolic blood pressure were observed. No changes in triglycerides or blood glucose levels were demonstrated.
No participant commenced medication for any risk factor during the study. Participants receiving medication for diabetes (n = 13), hypertension (n = 19) and/or dyslipidemia (n = 12) by definition, met the criteria for those respective MetS components at both evaluation time points making capture of improvements impossible. Excluding these, 30% (3/10) of unmedicated participants with hypertriglyceridemia, 67% (2/3) with hyperglycaemia and 21% (3/14) each for hyperglycaemia and hypertension at baseline no longer met these criteria post intervention. At baseline there were only 2 participants with MetS that was not contributed to by the use of medication. They remained unmedicated and were without MetS at intervention completion. No adverse events were noted.
With improvements in transplantation medicine, more patients can anticipate long-term survival following SCT. Risk factors for metabolic disease including excess weight and visceral adiposity occur frequently after SCT contributing to serious morbidity and premature mortality. The prevalence of MetS in our population of SCT survivors was considerable at 43% compared with an Australian adult population prevalence of 22.1%. 11 These results are supported by an observed 49% prevalence of MetS among allogeneic SCT survivors in the USA representing a 2.2-fold increase compared with age-and gender-matched controls. 4 Similarly, MetS appears to occur at a higher than expected rate in Italian autologous and allogeneic transplant survivors relative to the general Italian population. 3 It is unsurprising given the link between adiposity and proinflammatory cytokines which underpin insulin resistance and the development of the MetS, 3 that our data demonstrate a higher prevalence of MetS with increased BMI. Whilst the frequent use of corticosteroids following SCT is likely to contribute to obesity, insulin resistance and therefore MetS, it is unlikely that this is the sole contributing factor to what is a complex metabolic pathway in this cohort. The absence of differences between autologous and allogeneic SCT recipients in any measured parameter lends support to the notion that chemotherapy alone may be responsible for metabolic sequelae, however, the possibility of a survival bias for allogeneic transplant recipients participating in an intervention offered through a long-term follow-up clinic cannot be excluded.
As a diagnostic tool for MetS, the ATP-III criteria fails to differentiate between individuals meeting MetS criteria based on medication and those meeting criteria in the absence of medication. Consequently, the true effect of a lifestyle intervention program proves difficult to measure when therapeutic medications have already been instituted at baseline and are neither reviewed nor changed.
Optimisation of diet and increased physical activity are unquestionable prerequisites for long-term success in the management of MetS. The effectiveness of our intervention beyond standard care approaches, however, is difficult to determine. HDL-cholesterol is well established to be inversely associated with cardiovascular risk. 12 It is estimated that for every 0.026 mg/dL increase in HDL-cholesterol, cardiovascular disease risk is reduced by 2% in men and 3% in women. 13 Further, an increase in HDL-cholesterol of only 6% has been shown to reduce both coronary morbidity and mortality.
14 Controversy exists, however, as to whether improvements in HDL-cholesterol resulting from lifestyle interventions are independent of 129 (16) 128 ( Letter to the Editor weight loss with its known association with increases in HDL-cholesterol. 12 Weight loss of ⩾ 5% is generally considered to be clinically significant and shown to reduce cardiovascular risk at one year. 15 Few studies using physical activity interventions, however, result in ⩾ 3% decreases of baseline weight in overweight/obese individuals. Comparison with a matched historical group of post-SCT long-term follow-up clinic attendees receiving general health advice but not participating in the lifestyle intervention reveals that weight and waist circumference changes over 12 months differed significantly between this comparator group (mean increases of 1.0 kg (95% CI: − 0.13 to 2.15) and 1.3 cm (95% CI: − 0.05 to 2.6), respectively) and project participants, both Po 0.001. It is anticipated, therefore, that the additional prevention of weight gain compared with historical controls will add to the clinical benefit potential of our study.
Limitations of this study relate to the generalisability of the findings to a wider SCT population. Participants were recruited from an established long-term follow-up clinic in a single metropolitan tertiary hospital, potentially introducing selection bias. Clinic attendees may be particularly motivated to improve or maintain their health or have a more complicated post-transplant course. Their ongoing engagement in health care systems, however, provides an opportunity to use existing clinical reviews as a platform to embed health promotion strategies into optimal survivorship care.
Our data demonstrate the potential of a lifestyle intervention program to reduce the number or severity of MetS related risk factors in long-term survivors of SCT. Further research is required to identify if additional specific dietary modifications can lead to improved lipid profiling and greater MetS risk reduction in this population.
